Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
You may also be interested in...
The company launched the lab test in the US. New results from PATHFINDER trial showed an earlier version of Galleri can detect many types of cancer, including early-stage cancer that has yet to metastasize.
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.